A new strategy to enhance gene therapy for sickle cell disease
Researchers described a promising new approach for using gene therapy to treat sickle cell disease in the journal Human Gene ...
Here are 4 biotech stocks that could get a boost from a more open FDA regulatory climate
Biotech-stock investing has one tough test for success - and it's about to get easier ...
sicklecellanemianews1d
Celebrating a milestone in gene therapy for sickle cell disease
Wilson celebrates the first U.S. patient to complete gene therapy for sickle cell, but says advocacy must continue.
Morningstar1d
Biotech-stock investing has one tough test for success - and it's about to get easier
Skorney cited a drug called Oxbryta from Pfizer (PFE), which was approved to treat the blood disorder sickle cell. Instead of using clinical benefit as the benchmark, the FDA approved Oxbryta based on ...
2 High-Yield Dividend Stocks I Can't Stop Buying
High-yield dividend stocks have been gaining momentum ahead of potential Fed rate cuts. While sticky inflation and possible ...
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Good morning, and welcome to Fulcrum Therapeutics Third Quarter ...
Cautious Hold Rating on Fulcrum Therapeutics Amid Uncertain Prospects and Strategic Shifts
Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated ...
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024
Patient enrollment and site activation progressing in Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Ended the third quarter of 2024 with $257.2 million in cash, cash equivalents ...